• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sage Therapeutic Com (NQ: SAGE )

    13.96 -0.22 (-1.55%)
    Streaming Delayed Price Updated: 3:37 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 283,674
    Open 13.95
    Bid (Size) 13.95 (4)
    Ask (Size) 13.98 (4)
    Prev. Close 14.18
    Today's Range 13.90 - 14.48
    52wk Range 10.92 - 58.06
    Shares Outstanding 59,762,106
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
    SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
    From Sage Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -37.90%
    -37.90%
    1 Month
    -22.01%
    -22.01%
    3 Month
    -47.40%
    -47.40%
    6 Month
    -24.99%
    -24.99%
    1 Year
    -71.30%
    -71.30%

    More News

    Read More
    Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
    Via Benzinga
    Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
    Via Benzinga
    Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
    Via Benzinga
    Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Earnings Scheduled For February 14, 2024
    Via Benzinga
    Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
    From Sage Therapeutics, Inc.
    Via Business Wire
    Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
    From Sage Therapeutics, Inc.
    Via Business Wire
    Sage Therapeutics to Present at Upcoming March Investor Conferences
    From Sage Therapeutics, Inc.
    Via Business Wire
    These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
    Via Benzinga
    Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
    From Sage Therapeutics, Inc.
    Via Business Wire
    Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
    From Sage Therapeutics, Inc.
    Via Business Wire
    Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
    From Sage Therapeutics, Inc.
    Via Business Wire
    Sage Therapeutics Announces Changes to Board of Directors
    From Sage Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.